Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? @Themotleyfool #Stocks $VKTX

Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? @themotleyfool #stocks $VKTX

Key PointsViking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The healthcare company has an injectable version of its anti-obesity candidate in a phase 3 trial at the moment.The market valuation for Viking Therapeutics seems low when you consider the company's remaining development pipeline.10 stocks we like better than Viking Therapeutics › As of Aug. 20, shares of Viking Therape…

Viking Therapeutics Stock Drops on Study Results - PressReach

Viking Therapeutics recently experienced a significant drop in its stock price following the release of results from a clinical study on its oral weight-loss drug. The study aimed to evaluate the efficacy and safety of the treatment, but investors reacted negatively to the findings, leading to a substantial decline in the company’s market value. The clinical trial, which was a critical phase in the drug development process, showed that the oral …

Viking Therapeutics Stock Crashes 42%: After Disappointing Obesity Drug Trial

Why did Viking Therapeutics stock drop after its obesity drug trial update? Viking Therapeutics shares slumped sharply this week after the company’s latest obesity drug trial update failed to match lofty investor expectations. The stock, which had been climbing steadily through August, dropped 42% on Tuesday, tumbling from above $42 to a $24.36 close. Pre-market trade on Wednesday shows VKTX still under pressure, hovering around $24.70. The reac…